Reimbursement Review Reports


( Last Updated : February 3, 2023)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBC filgrastim Cancelled
Ogivri Trastuzumab Withdrawn
Zytiga Abiraterone Withdrawn
Admelog Insulin lispro Cancelled
TBD Cabozantinib Withdrawn
Erbitux Cetuximab Cancelled
Firazyr icatibant CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete
Ibrance Palbociclib Withdrawn
Beleodaq Belinostat Withdrawn